Association of plasma trace element levels with neovascular age-related macular degeneration by Heesterbeek, T.J. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2021-11-05 and may be subject to
change.
Experimental Eye Research 201 (2020) 108324
Available online 21 October 2020
0014-4835/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Association of plasma trace element levels with neovascular age-related 
macular degeneration 
Thomas J. Heesterbeek a,1, Mansour Rouhi-Parkouhi b,1, Stephanie J. Church d, 
Yara T. Lechanteur a, Laura Lorés-Motta a,e, Nikolaos Kouvatsos b, Simon J. Clark f,g, 
Paul N. Bishop f,h, Carel B. Hoyng a, Anneke I. den Hollander a,e, Richard D. Unwin i, 
Anthony J. Day b,c,* 
a Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands 
b Wellcome Trust Centre for Cell-Matrix Research, Division of Cell-Matrix Biology & Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine 
and Health, University of Manchester, Manchester Academic Health Science Centre, Oxford Road, Manchester, M13 9PT, UK 
c Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science 
Centre, Oxford Road, Manchester, M13 9PT, UK 
d Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Core Technology Facility, 
Grafton Street, Manchester, M13 9NT, UK 
e Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands 
f Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PT, 
UK 
g Institute for Ophthalmic Research, Eberhard Karls University of Tübingen, Elfriede-Aulhorn-Straße 7, 72076, Tübingen, Germany 
h Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester M13 9WL, UK 
i Stoller Biomarker Discovery Centre and Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, 
CityLabs 1.0 (3rd Floor), Nelson Street, Manchester, M13 9NQ, UK   
A R T I C L E  I N F O   
Keywords: 






A B S T R A C T   
Although the triggers causing angiogenesis in the context of neovascular age-related macular degeneration 
(nAMD) are not fully understood, oxidative stress is likely involved. Oxidative stress in the eye can occur through 
exposure of macular tissues to sunlight and local or systemic exposure to oxidative stressors associated with 
environmental or lifestyle factors. Because trace elements have been implicated as regulators of oxidative stress 
and cellular antioxidant defense mechanisms, we hypothesized that they may play a role as a risk factor, 
modifying the progression toward nAMD. 
Herein, we determined whether levels of human plasma trace elements are different in 236 individuals with 
nAMD compared to 236 age-matched controls without AMD. Plasma levels of 16 trace elements including 
arsenic, barium, calcium, cadmium, cobalt, chromium, copper, iron, magnesium, manganese, molybdenum, lead, 
antimony, selenium, vanadium and zinc were measured using inductively coupled plasma mass spectrometry. 
Abbreviations: Al, aluminum; AMD, age-related macular degeneration; ANOVA, analysis of variance; As, arsenic; Ba, barium; Bi, bismuth; BM, bruch’s membrane; 
BMI, body mass index; Ca, calcium; Cd, cadmium; Ce, cerium; CFP, color fundus photographs; CIRCL, Cologne Image Reading Center and Laboratory; Co, cobalt; Cr, 
chromium; Cu, copper; EUGENDA, European Genetic Database; ETDRS, Early Treatment Diabetic Retinopathy Study; FA, fluorescein angiography; FDR, false dis-
covery rate; Fe, iron; GA, geographic atrophy; Ge, germanium; He, helium; I-AS, Agilent Integrated autosampler; ICGA, indocyanine green angiography; ICP-MS, 
inductively coupled plasma mass spectrometry; IQR, interquartile range; In, indium; K, potassium; Li, lithium-6; LOCS, lens opacity classification system; LOQ, limit 
of quantification; MDA, malondialdehyde; Mg, magnesium; Mn, manganese; Mo, molybdenum; Na, sodium; nAMD, neovascular age-related macular degeneration; 
Ni, nickel; NIST, National Institute of Standards and Technology; NSAIDs, Nonsteroidal anti-inflammatory drugs; OCT, optical coherence tomography; OR, odds ratio; 
Pb, lead; ROS, reactive oxygen species; RPE, retinal pigment epithelium; Sb, antimony; Sc, scandium; SD, standard deviation; Se, selenium; smMIPs, single molecule 
molecular inversion probes; SRM, Standard Reference Material; Tb, terbium; Tl, thallium; V, vanadium; VEGF, vascular endothelial growth factor; Y, yttrium; Zn, 
zinc. 
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Associations of trace elements with demographic, environmental and lifestyle factors and AMD-associated ge-
netic variants were assessed. 
Elevated levels of barium and cadmium and reduced levels of chromium were observed in nAMD patients 
compared to controls. Mean plasma concentrations of barium were 1.35 μg/L (standard deviation [SD] 0.71) in 
nAMD and 1.15 μg/L (SD 0.63) in controls (P = 0.001). Mean levels of chromium were 0.37 μg/L (SD 0.22) in 
nAMD and 0.46 μg/L (SD 0.34) in controls (P = 0.001). Median levels for cadmium, which were not normally 
distributed, were 0.016 μg/L (interquartile range [IQR] 0.001–0.026) in nAMD and 0.012 μg/L (IQR 
0.001–0.022) in controls (P = 0.002). Comparison of the Spearman’s correlation coefficients between nAMD 
patients and controls identified a difference in correlations for 8 trace elements. Cadmium levels were associated 
with the smoking status (P < 0.001), while barium levels showed a trend of association with the usage of 
antihypertensive drugs. None of the AMD-associated genetic variants were associated with any trace element 
levels. 
In conclusion, in this case-control study we detected elevated plasma levels of barium and cadmium and 
reduced plasma levels of chromium in nAMD patients. An imbalance in plasma trace elements, which is most 
likely driven by environmental and lifestyle factors, might have a role in the pathogenesis of AMD. These trace 
elements may be incorporated as biomarkers into models for prediction of disease risk and progression. Addi-
tionally, population-based preventive strategies to decrease Cd exposure, especially by the cessation of smoking, 
could potentially reduce the burden of nAMD. Future studies are warranted to investigate whether supple-
mentation of Cr would have a beneficial effect on nAMD.   
1. Introduction 
Age-related macular degeneration (AMD) is a complex, multifacto-
rial retinal disease and one of the leading causes of severe vision loss 
globally in those over 50 years of age (Jonas et al., 2017). As the de-
mographic, environmental, genetic, and phenotypic underpinnings of 
AMD becomes better understood, a combination of innovative screening 
and assessment could enable the development of risk models and novel 
preventive strategies (Panattoni et al., 2011). The most consistently 
reported demographic, environmental and lifestyle risk factors for AMD 
include advanced age, smoking and obesity (Colijn et al., 2017; Velilla 
et al., 2013; Zhang et al., 2016). In addition, studies show mixed results 
regarding the involvement of the cardiovascular system in AMD, 
including hypertension, pulse pressure and circulating lipids (Hyman 
et al., 2000; Pennington and DeAngelis, 2016). Recently, 52 common 
and rare genetic variants at 34 loci have been associated with AMD, 
which particularly involve the complement system, lipid metabolism 
and extracellular matrix (Fritsche et al., 2016). The two most important 
phenotypic risk factors for disease progression in AMD are drusen and 
subretinal drusenoid deposits, which are extracellular deposits in the 
retina between the Bruch’s membrane (BM) and retinal pigment 
epithelium (RPE), and RPE and photoreceptor layer, respectively (Chen 
et al., 2020). Patients with drusen and subretinal drusenoid deposits can 
eventually progress to late stage AMD, which can be distinguished as 
two subtypes: geographic atrophy (GA) and neovascular AMD (nAMD). 
While the development of GA involves a gradual degeneration of pho-
toreceptors, RPE and the choriocapillaris, nAMD is characterized by a 
relatively rapid process of neovascularization from blood vessels in the 
choriod (i.e. under the macular region) into the retina. Although the 
triggers for angiogenesis in nAMD patients are not fully understood, 
inflammation and oxidative stress are likely involved. 
Oxidative stress is an important contributor to the development of 
AMD. Oxidative stress in the eye can occur in many forms via a variety of 
stimuli. Local exposure of sunlight leads to a high predisposition for 
oxidative burden (Taylor et al., 1990). When combined with systemic 
exposure to oxidative stressors, incurred via lifestyle factors such as 
smoking, the relative burden of oxidative stress can rapidly become 
disproportionately high (Wang et al., 2009; Yuan et al., 2010). Oxidative 
stress generates reactive oxygen species (ROS) that damage the cell and 
matrix components in the RPE, BM, and choroid, and provides signals 
for inflammation and angiogenesis, leading to the development and 
progression of nAMD (Datta et al., 2017; Shaw et al., 2016). 
Trace elements have been implicated as regulators of oxidative stress 
in other contexts (Stelling et al., 2019). Several studies have shown that 
metal ions such as cadmium (Cd), iron (Fe), and lead (Pb) can be 
detected in ocular tissues of human eyes (Dunaief, 2006; Erie et al., 
2005; Langford-Smith et al., 2016). These trace elements are thought to 
be involved in the pathogenesis of nAMD by increasing chronic oxida-
tive stress and decreasing antioxidant defense systems (World Health 
Organization, 1996). Cd has been found to be significantly higher in 
blood samples of smokers compared to non-smokers (Li et al., 2019), and 
is associated with a higher incidence of nAMD (Kim et al., 2016; Park 
et al., 2015). Furthermore, a secondary analysis of the Comparisons of 
AMD Treatments Trials showed that the use of iron supplements was 
associated with nAMD in a dose-response manner (Song et al., 2018). 
Other metal ions such as chromium (Cr), copper (Cu), magnesium (Mg), 
manganese (Mn), selenium (Se) and zinc (Zn) are known to be involved 
in cellular antioxidant defense mechanisms (Lee et al., 2019; Salmono-
wicz et al., 2014). In AMD patients, supplementation of Zn has shown to 
be beneficial in reducing the progression of the disease (Age-Related Eye 
Disease Study Research Group, 2001; van Asten et al., 2019). Moreover, 
elderly individuals have generally a higher risk to develop trace element 
deficiencies due to modified dietary habits, age related physiological 
changes, drug therapy, and chronic diseases (Ekmekcioglu, 2001). 
Together these findings suggest that there may be a role for altered 
levels of essential trace elements in modifying the progression toward 
nAMD. 
Whilst direct measurement of trace element levels in the retina 
provides accurate and reliable data, tissue biopsies are invasive tech-
niques, not easily obtained and not feasible for risk assessment in large 
populations. Conversely, systemic measurements are less invasive, 
quicker and more easily repeatable. Since blood is a source for trace 
elements entering the eye (Abokyi et al., 2020), it was hypothesized that 
analyzing plasma trace element levels in nAMD patients would be 
informative; i.e. especially as there is limited data available in the 
literature on plasma trace element levels in nAMD. Therefore, the main 
purpose of the current study was to identify novel systemic biomarkers 
for nAMD by investigating plasma metal ion and metalloid levels, 
comparing patients with nAMD and age-matched controls. Quantitative 
data were obtained for 13 metal ions (barium (Ba), calcium (Ca), Cd, 
cobalt (Co), Cr, Cu, Fe, Mg, Mn, molybdenum (Mo), Pb, vanadium (V) 
and Zn), 2 metalloids (arsenic (As) and antimony (Sb)) and one 
non-metal (Se) in plasma samples from 236 nAMD patients and 236 
controls. Secondly, we explored the underlying mechanisms of our 
findings by investigating the association of the 16 plasma trace element 
levels with demographic, environmental and lifestyle factors, as well as 
with AMD-associated variants at 34 genomic loci. 
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2. Material and methods 
2.1. Study participants 
Study participants with available plasma samples were recruited 
from the European Genetic Database (EUGENDA), a multicenter data-
base for clinical and molecular analysis of AMD from Nijmegen, the 
Netherlands, and Cologne, Germany. Written informed consent was 
obtained for all individuals participating in the study, which was per-
formed according to the guidelines of the Declaration of Helsinki and 
with local ethics committee approval (Arnhem-Nijmegen Commission 
for Human Research). To prevent bias caused by the study site only 
individuals from the Nijmegen cohort were selected from the database. 
For every individual patient with neovascular AMD (nAMD), a control 
was manually identified from the database (with an age difference <0.5 
years). According to this approach, we were able to include a total of 236 
nAMD patients and 236 age-matched controls, who had entered the 
EUGENDA database between 2006 and 2015. All patients with nAMD 
had been treated in the past with injections of anti-angiogenic drugs. 
Retinal images were assessed by certified graders based on the protocol 
of the Cologne Image Reading Center and Laboratory (CIRCL) an AMD 
classification that was adopted specifically for EUGENDA based on 
different international staging systems (Bird et al., 1995; van Leeuwen 
et al., 2003). The diagnosis of nAMD was based on multimodal grading 
of images obtained via color fundus photographs (CFP) only (n = 24, 
[10%]), a combination of CFP and optical coherence tomography (OCT) 
(n = 105, [44%]), a combination of CFP and fluorescein angiography 
(FA), and/or indocyanine green angiography (ICGA) (n = 85, [36%]), or 
a combination of CFP, OCT and FA/ICGA (n = 22, [10%]). At the time of 
inclusion, patients with nAMD presented with choroidal neo-
vascularization (CNV) within the Early Treatment Diabetic Retinopathy 
Study (ETDRS) grid secondary to AMD with or without signs of CNV 
activity (hemorrhage on CFP and/or leakage on FA and/or subretinal 
and/or intraretinal fluid on OCT). Controls included participants with 
no drusen, only small drusen (<63 μm), only pigmentary abnormalities, 
or <10 small drusen and pigment abnormalities, as defined by the CIRCL 
grading protocol (Heesterbeek et al., 2020). 
2.2. Demographic, environmental and lifestyle factors 
Information on demographic, environmental and lifestyle factors 
was obtained through detailed interviewer-assisted questionnaires. 
Variables included in this study were age in years (<65; 65–70; 70–75; 
75+), sex (male; female), smoking (never; past; current), body mass 
index (BMI) calculated as weight in kilograms divided by height in 
meters squared (normal [<25]; overweight [25–30]; obese [>30]), 
having metal implants including hip or knee prosthesis (yes; no), using 
nutritional supplements (yes; no), using lipid lowering drugs (yes; no), 
using antidiabetic drugs (yes; no), using antihypertensive drugs (yes; 
no), using thrombocyte inhibitors (yes; no), using nonsteroidal anti- 
inflammatory drugs (NSAIDs; yes; no), using corticosteroids (yes; no), 
meat consumption in general (yes; no), fish consumption in general (yes; 
no), alcohol consumption in general (yes; no), daily fruit consumption 
(yes; no), and daily vegetable consumption (yes; no). In addition, during 
a physical examination, the degree of lens opacification was determined 
and quantified using the Lens Opacity Classification System (LOCS). 
Participants with a LOCS score 1–2 were categorized as having no 
cataract, while participants with a LOCS score 3–4 were categorized as 
having cataract. 
2.3. Genetic variants 
Genomic DNA was isolated from venous blood lymphocytes and 
genotyping was performed for AMD-associated variants at 34 loci using 
single molecule molecular inversion probes (smMIPs) and next genera-
tion sequencing as part of the Eyerisk Project (de Breuk et al., 2020). 
smMIPs are single stranded DNA molecules and contain sequences that 
are complementary to the target in the genome, which in this case allows 
the identification of alleles of the AMD-associated variants for every 
participant. Genetic variants analyzed in the current study included CFH 
(rs10922109 and rs570618), COL4A3 (rs11884770), ADAMTS9-AS2 
(rs62247658), COL8A1 (rs140647181), CFI (rs10033900), C9 
(rs62358361), PRLR/SPEF2 (rs74767144), C2/CFB/SKIV2L 
(rs116503776), VEGFA (rs943080), KMT2E/SRPK2 (rs1142), PILRB/-
PILRA (rs7803454), TNFRSF10A (rs79037040), MIR6130/RORB 
(rs10781182), TRPM3 (rs71507014), TGFBR1 (rs1626340), ABCA1 
(rs2740488), ARHGAP21 (rs12357257), ARMS2/HTRA1 (rs3750846), 
RDH5/CD36 (rs3138141), ACAD10 (rs61941272), B3GALTL 
(rs9564692), RAD51B (rs61985136), LIPC (rs2043085), CETP 
(rs5817082), CTRB2/CTRB1 (rs55993634), TMEM97/VTN 
(rs11080055), NPLOC4/TSPAN10 (rs6565597), C3 (rs2230199), CNN2 
(rs113772652), APOE (rs429358), MMP9 (rs142450006), C20orf85 
(rs117420707), SYN3/TIMP3 (rs5754227) and SLC16A8 (rs8135665). 
2.4. Trace element measurements 
Plasma samples were collected using tubes containing anticoagulant 
and blood cells were removed by centrifugation; samples were processed 
and stored at -80 ◦C within 1 h of collection. Prior to trace element 
quantitation by inductively coupled plasma mass spectrometry (ICP- 
MS), plasma samples of cases and controls (150 μL), or serum controls 
from the National Institute of Standards and Technology (NIST) (150 μL; 
see below), were combined with a 1.3 mL solution of 1% (v/v) Ultrapure 
NORMATOM nitric acid (VWR; catalogue no. 83879.230), 0.5% (v/v) 
HPLC-grade butanol (Sigma; 34867), 0.01% (v/v) Triton X-100 (Sigma; 
X100-500ML) and 0.1% Agilent Internal Standard mixture (containing 
10 μg/mL of bismuth (Bi), germanium (Ge), indium (In), scandium (Sc), 
terbium (Tb), yttrium (Y) and lithium-6 (Li) (in 5% (v/v) HNO3 (Agilent 
Technologies; 5183–4681)) in LC/MS grade water (Fisher Chemical; 
10505904), mixed and then 50 μL of 2% (v/v) nitric acid was added, i.e. 
to give a final volume of 1.5 mL (1 in 10 dilution). This protocol was 
adapted from the method of Cesbron et al. (2013) and validated with 
reference to certified values for Cd, Co, Cu, Fe, Mn, nickel (Ni), Sb, Se, V 
and Zn in Standard Reference Material (SRM) 1598a from NIST, USA; 
NIST also supply reference values for aluminium (Al), Ca, Cr and Mo and 
an information value for As in this standard. A total of 18 trace elements 
were measured using ICP-MS: Al, As, Ba, Ca, Cd, Co, Cr, Cu, Fe, Mg, Mn, 
Mo, Ni, Pb, Sb, Se, V and Zn. 
Trace element concentrations were measured using an Agilent 7700x 
ICP-MS spectrometer equipped with a MicroMist nebulizer (Glass 
Expansion, Melbourne, Australia) and a Scott double-pass spray cham-
ber, using a multi-element method including all elements present in the 
calibration solution (Church et al., 2015; Xu et al., 2017). Calibration 
solutions were produced by appropriate dilutions of Environmental 
Calibration Standard (Agilent 5183–4688) for each batch of samples; a 
full range of standard concentrations were analyzed at the beginning of 
each batch with an intermediate concentration from this calibration 
series run approx. every 10 samples to ensure there is no instrument 
drift. Instrument and dilution blanks were also run periodically in each 
experiment and the detection limit for each element was determined by 
comparison of calibration samples and blanks. The instrument was 
tuned prior to each run according to manufacturer’s recommendations 
using a tuning solution containing 10 μg/L Li, Y, cerium (Ce), thallium 
(Tl), and Co in 2% (v/v) HNO3 (Agilent; 5184–3566). Sample intro-
duction was performed using an Agilent Integrated Autosampler (I-AS) 
with helium (He) as the collision gas. Ge was used as the internal 
standard for Mg, Al, Ca, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, As and Se; In was 
used as the internal standard for Mo, Cd, Sb, Ba and Pb. Two collision 
cell gas modes were applied: all elements were analyzed in helium mode 
(5.0 mL/min He), except for Se that was analyzed in high-energy helium 
mode (10 mL/min He) and for Ge and In, which were analyzed in both 
modes; mode selection followed Agilent recommendations. Integration 
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times were: 0.01 s for Fe; 0.1 s for Mg, Ca, Sb, Ba and Pb; 0.2 s for V and 
Co; 0.3 s for Mn, Cu, Zn and Mo; 0.5 s for Ni; 0.7 s for Cr; 1 s for Al and 
Cd; 1.5 s for As; and 3 s for Se. Sample trace element concentrations were 
automatically calculated by the software employed (Mass Hunter, Agi-
lent). Data were exported to Microsoft Excel and corrected for dilution. 
During the measurements, samples were divided into 10 batches 
consisting of 5 × 50, 3 × 52, 1 × 46 and 1 × 20 samples. Each batch 
included both cases and their age-matched controls. SRM 1598a from 
NIST, which is derived from a mixture of healthy bovine and porcine 
sera, was used as an internal validation control, with triplicate standards 
analyzed in each batch to provide evidence of accuracy of trace element 
measurements and reproducibility between batches (Supplementary 
Table 1); 5 blanks (prepared as for the samples and NIST standards but 
lacking plasma/serum) were also included. To minimize contamination 
high-grade solvents and metal-free plastics were used throughout. 
Contamination was measured by inclusion of ‘blank’ samples within 
each batch. Al and Ni measurements were excluded, since these metal 
ions exceeded a coefficient of variance of 40% in the SRM 1598a con-
trols, which indicated inadequate accuracy and reproducibility between 
batches; this was attributed to levels below our limit of detection (for Ni; 
likely due to the use of Ni cones in the ICP-MS) or the presence of var-
iable trace-level contamination (for Al). For the other trace elements, 
values that were measured below the limit of quantification (LOQ) in a 
particular batch were substituted by LOQ/2, since excluding these 
measurements would have introduced significant bias (Helsel, 1990). 
Substitution of these values was done in a batch-specific manner by 
using the LOQ of the particular batch. Measurements for 16 trace ele-
ments were included in the further analyses (Supplementary Table 1). 
2.5. Statistical analysis 
Statistical analyses were conducted using SPSS (IBM, version 25). 
Demographic differences between nAMD patients and controls were 
assessed using independent t-tests and chi-squared tests. Levels of nor-
mally distributed trace elements were compared between nAMD pa-
tients and controls using independent t-tests, whereas non-normally 
distributed trace elements were tested with a Kruskal-Wallis H test. In 
addition, to explore possible underlying mechanisms, the association of 
trace element levels with demographic, environmental, lifestyle and 
genetic factors was evaluated; again, independent t-tests for normally 
distributed trace elements and Kruskal Wallis H test for non-normally 
distributed trace elements were used. For all these statistical analyses, 
P values below 0.003 were considered statically significant, which cor-
responds to a Bonferroni correction for 16 covariates (Bender and Lange, 
2001). The significant AMD-associated trace elements were thereafter 
analyzed in a multifactorial binary logistic regression model, adjusting 
for the relevant demographic, environmental and lifestyle factors. 
To investigate the correlation between individual trace elements, a 
Spearman’s rho rank correlation between the trace elements was 
calculated. Due to the strong correlations between trace elements, 
correction for multiple testing in this analysis was performed by 
applying the Benjamini-Hochberg procedure, a false discovery rate 
(FDR) correction (Benjamini and Hochberg, 1995). A significance 
threshold of PFDR-value <0.05 after FDR correction was applied to this 
analysis. Correlation coefficients between trace elements were 
compared between nAMD patients and controls using the “r. test” 
function of the “psych” package. 
3. Results 
3.1. Demographics 
This study included 236 nAMD patients and 236 unaffected controls. 
Sex was not used as a selection criteria, nonetheless, by chance, the sex 
distribution was the same in the nAMD group and controls (56% female 
in both). The mean age of the nAMD patients and of the age-matched 
controls was 73.5 years. There were significantly more current 
smokers in the nAMD group compared to controls (22% vs 6%, P <
0.001). There was also a higher use of alcohol (40% vs 31%, P = 0.043), 
supplements (36% vs 10%, P < 0.001), antidiabetic drugs (9% vs 4%, P 
= 0.016) and antihypertensive drugs (47% vs 37%, P = 0.032) among 
patients with nAMD compared to controls (Table 1). In addition, nAMD 
patients were more frequently pseudophakic (i.e. having had their lens 
removed during cataract surgery) compared to controls (30% vs 18%, P 
= 0.012), but phakic nAMD patients (i.e. with natural lenses) did not 
have a greater prevalence of cataract compared to phakic controls (32% 
vs 37%, P = 0.382). Other demographic parameters (including sex, BMI 
and presence of metal implants) did not differ significantly between 
cases and controls. 
3.2. Quality control 
In our study, we obtained quality controlled ICP-MS data for 16 trace 
elements (Supplementary Table 1). For Ca, Cd, Cu, Fe, Sb, Se, V and Zn 
the mean values determined for these trace elements in the NIST con-
trols were within 15% of supplied values; for As, Co, Cr, Mn and Mo they 
were within 22–35%. Mean values for Ba and Mg in the nAMD case- 
control samples, for which reference values were not available, were 
in good agreement with published data, whereas the levels of Pb were 
somewhat lower than some reported previously (Bergdahl et al., 2006; 
Cesbron et al., 2013; Jahnen-Dechent and Ketteler, 2012). Three of the 
16 trace elements included in the analysis had values outside the LOQ 
[Cd (165 samples, 35%), Pb (213 samples, 45%) and V (54 samples, 
12%)]. For V, the distribution of values below the LOQ was essentially 
identical between nAMD patients (6%) and controls (6%). However, for 
Cd and Pb the values below the LOQ were more frequently found in 
controls; 15% in nAMD vs 20% in controls for Cd (P = 0.015), and 20% 
in nAMD vs 25% in controls for Pb (although not significant; P = 0.065). 
All trace elements, except As, Cd and Pb, showed a normal distribution 
in patients and controls. Therefore, parametric tests were used for the 
analysis of all trace elements, except for As, Cd and Pb, for which 
non-parametric tests were used instead. 
3.3. Association between trace elements and neovascular AMD 
Patients with nAMD had higher plasma Ba and Cd levels, and lower 
plasma Cr levels compared to controls (Table 2). Mean levels for Ba were 
1.35 μg/L (standard deviation [SD] 0.71) in nAMD patients and 1.15 μg/ 
L (SD 0.63) in controls (P = 0.001) and mean levels of Cr were 0.37 μg/L 
(SD 0.22) in nAMD patients and 0.46 μg/L (SD 0.34) in controls (P =
0.001). Median levels for Cd, which were not normally distributed, were 
0.016 μg/L (interquartile range [IQR] 0.001–0.026) in nAMD patients 
and 0.012 μg/L (IQR 0.001–0.022) in controls (P = 0.002). 
3.4. Correlation among trace elements 
Next, we analyzed the correlation among plasma trace elements. 
After applying FDR correction, Spearman’s rho correlations showed 
several trace elements that were significantly correlated in both nAMD 
patients and controls (Fig. 1 and Supplementary Table 2). Comparison of 
the Spearman’s correlation coefficients between nAMD patients and 
controls identified a difference in correlations for 8 trace elements. For 
example, there is a negative correlation between Ba and Co levels and a 
positive correlation between Ba and Mn levels in the nAMD cohort, 
which is not seen in controls (Table 3). 
3.5. Association between trace elements and demographic, environmental 
and lifestyle factors 
Then, we investigated the association of the 16 trace elements with 
several demographic, environmental and lifestyle factors (Table 4). P 
values below 0.003 were considered statically significant, which 
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corresponds to a Bonferroni correction for 16 covariates. Cd levels were 
significantly associated with the smoking status of the participants 
(never smoked 0.011 μg/L, smoked in the past 0.014 μg/L and current 
smoking 0.021 μg/L, P < 0.001). There was a trend for higher Ba levels 
in patients using antihypertensive drugs compared to patients not using 
such drugs (1.355 μg/L vs 1.173 μg/L, P = 0.005), however, this trend 
did not reach the Bonferroni significance threshold. Cr was not signifi-
cantly associated with any of the investigated demographic, environ-
mental and lifestyle factors (P > 0.003). 
For the non-AMD associated trace elements, higher age was associ-
ated with higher Mg levels, female sex was associated with higher Cu 
levels and lower Fe levels, smoking was associated with higher Fe levels 
and higher Pb levels, having metal implants was associated with higher 
Co levels, using supplements was associated with higher Cu levels and 
higher Zn levels, using antidiabetic drugs was associated with lower Mg 
levels, fish consumption was associated with higher As levels and higher 
Se levels, and alcohol consumption was associated with higher Se levels. 
As shown in Table 4, all of these trace elements were significantly 
associated with these demographic, environmental or lifestyle factors (P 
< 0.003), but they were not significantly associated with nAMD in this 
study (Table 2). None of the trace elements were significantly associated 
with having cataract in combined nAMD patients and controls (Table 4) 
or when just controls were analyzed (Supplementary Table 3). 
3.6. Association between trace elements and genetic variants 
Next, we analyzed the association of the 16 trace elements with 
AMD-associated variants, in which we also considered a P value below 
0.003 as statistically significant. As can be seen in Supplementary Table 
4, none of the AMD-associated variants at the 34 genomic loci were 
significantly associated with any of the trace elements (P > 0.003). 
3.7. Risk model for neovascular AMD based on trace elements 
Finally, multivariate logistic regression was used for estimating the 
odds of having nAMD based on the plasma values of Ba, Cd and Cr, 
adjusting for all demographic, environmental and lifestyle confounders 
including: age, sex, smoking status, BMI, having metal implants, using 
supplements, lipid lowering drugs, antidiabetic drugs, thrombocyte in-
hibitors, NSAIDs and corticosteroids, and consuming meat, fish, alcohol, 
fruit and vegetables. As can be seen in Table 5, all three trace elements 
remained significantly associated with nAMD after adjustment for the 
confounders (Ba: OR 1.55 per μg/L, Cd: OR 1.02 per ng/L, and Cr: OR 
0.09 per μg/L). 
4. Discussion 
In order to obtain a comprehensive overview of circulating trace 
elements in nAMD, we analyzed 16 plasma metal ions, metalloids and a 
non metal in 236 patients with nAMD and 236 age-matched controls 
using mass spectrometry. We detected elevated plasma levels of Ba and 
Cd and reduced plasma levels of Cr in nAMD patients compared to 
controls. Additional analysis showed that Cd levels were predominantly 
associated with the smoking status of participants, and Ba levels showed 
a trend towards association with the usage of antihypertensive drugs. Cr 
levels was not associated with any of the demographic, environmental 
and lifestyle factors. The AMD-associated genetic variants were not 
associated with any of the plasma trace elements. 
A limited number of studies have been performed to date on circu-
lating trace element levels in AMD patients, and these studies focused on 
either single measurements or at most five trace elements simulta-
neously (Aranaz et al., 2020; Cardinault et al., 2005; Damar Gungor 
et al., 2018; Kim et al., 2014, 2016; Mayer et al., 1998; Park et al., 2015; 
Tsang et al., 1992; Wu et al., 2014; Wysokinski et al., 2013). In line with 
our results, most of these studies found higher systemic Cd levels in AMD 
patients, especially within the smoking population (Kim et al., 2014, 
Table 1 
Demographic table.   
Controls (n =
236) 
nAMD patients (n 
= 236) 
P-value 
Age in years (mean (SD)) 73.48 (6.70) 73.49 (6.67) 0.993 
Sex, Female (n, (%)) 132 (56%) 132 (56%) 1.0 
BMI (mean (SD)) 26.0 (3.8) 26.4 (3.7) 0.175 
Smoking status (n, (%))   <0.001 
Never 88 (37%) 66 (28%)  
Past 133 (57%) 119 (50%)  
Current 15 (6%) 51 (22%)  
Daily vegetables consumption 
(n, (%))   
0.889 
Yes 206 (87%) 207 (88%)  
No 30 (12%) 29 (12%)  
Daily fruit consumption (n, 
(%))   
0.117 
Yes 192 (81%) 178 (75%)  
No 44 (19%) 58 (25%)  
Meat consumption (n, (%))   0.765 
Yes 212 (90%) 210 (89%)  
No 24 (10%) 26 (11%)  
Fish consumption (n, (%))   0.450 
Yes 183 (78%) 176 (75%)  
No 53 (22%) 60 (25%)  
Alcohol consumption (n, (%))   0.043 
Yes 73 (31%) 94 (40%)  
No 163 (69%) 142 (60%)  
Supplement intake (n, (%))   <0.001 
Yes 24 (10%) 86 (36%)  
No 212 (90%) 150 (64%)  
Lipid lowering drugs (n, (%))   0.246 
Yes 55 (23%) 66 (28%)  
No 181 (77%) 170 (72%)  
Antidiabetic drugs (n, (%))   0.016 
Yes 9 (4%) 22 (9%)  
No 227 (96%) 214 (91%)  
Antihypertensive drugs (n, 
(%))   
0.032 
Yes 87 (37%) 110 (47%)  
No 149 (63%) 126 (53%)  
Thrombocyte inhibitors (n, 
(%))   
0.088 
Yes 41 (17%) 56 (24%)  
No 195 (83%) 180 (76%)  
NSAIDs (n, (%))   0.823 
Yes 10 (4%) 11 (5%)  
No 226 (96%) 225 (95%)  
Corticosteroids (n, (%))   0.356 
Yes 20 (8%) 27 (11%)  
No 216 (92%) 209 (89%)  
Metal implants (n, (%))   0.204 
Yes 33 (14%) 24 (10%)  
No 203 (86%) 212 (90%)  
Lens status (n, (%))   0.012 
Pseudophakic 32 (18%) 48 (30%)  
Phakic 142 (82%) 111 (70%)  
If Phakic, having cataract   0.382 
No (LOCS 1–2) 97 (68%) 70 (63%)  
Yes (LOCS 3–4) 45 (32%) 41 (37%)  
Analyses are based on independent t-tests and chi-square tests. Abbreviations: 
BMI, Body Mass Index; LOCS, lens opacity classification system; nAMD, neo-
vascular age-related macular degeneration; NSAIDs, nonsteroidal anti- 
inflammatory drugs. 
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2016; Wu et al., 2014). These results are also consistent with histology 
studies, which showed Cd accumulation in the neurosensory retina and 
RPE of eyes affected by AMD and in those who smoked (Wills et al., 
2008, 2009). Cd is thought to gain access to the RPE via transport from 
the choroid by carrier proteins or metal transport mechanisms, such as 
zinc transporters ZIP4 and ZIP8 at the basal surface of the RPE that have 
a high affinity for Cd (Girijashanker et al., 2008; He et al., 2006). Within 
RPE cells, Cd is also able to interfere with the metabolism of Zn by 
competing for its binding to metallothioneins, which display a much 
greater affinity for Cd than for Zn (Gonzalez-Iglesias et al., 2014). Zn 
made bioavailable in this way could also potentially affect complement 
activity; e.g. by binding to complement factor H and C3, thereby 
Table 2 
Results of plasma trace elements in 236 nAMD patients compared to 236 controls. 
Analyses are based on independent t-tests for normally distributed trace elements, and Kruskal-Wallis H tests for non-normally 
distributed trace elements. Grey bars denote trace elements for which there was a significant difference between nAMD patients 
and controls after applying Bonferroni correction for 16 covariates (the bonferoni adjusted threshold for statistical significance was 
defined as P < 0.003). Abbreviations: As, arsenic; Ba, barium; Ca, calcium; Cd, cadmium; Co, cobalt; Cr, chromium; Cu, copper; Fe, 
iron; IQR, interquartile range; Mg, magnesium; Mn, manganese; Mo, molybdenum; nAMD, neovascular age-related macular 
degeneration; Pb, lead; Sb, antimony; SD, standard deviation; Se, selenium; V, vanadium; Zn, zinc. 
Fig. 1. Spearman’s correlation between plasma trace elements in nAMD patients and controls. Left-hand side: Correlations are depicted as observed in the controls. 
Right-hand side: Correlations in nAMD patients. Colors indicate positive (red) and negative (blue) correlations between the different trace elements, and significant 
correlations (PFDR-value <0.05) after FDR correction are indicated with an asterix (*). Black bordered squares are those correlations that were significantly different 
between nAMD patients and controls (Table 3). Supplementary Table 2 provides all plasma trace element correlations in nAMD patients and controls in more detail. 
Abbreviations: As, arsenic; Ba, barium; Ca, calcium; Cd, cadmium; Co, cobalt; Cr, chromium; Cu, copper; Fe, iron; Mg, magnesium; Mn, manganese; Mo, molyb-
denum; nAMD, neovascular age-related macular degeneration; Pb, lead; Sb, antimony; Se, selenium; V, vanadium; Zn, zinc. (For interpretation of the references to 
color in this figure legend, the reader is referred to the Web version of this article.) 
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inhibiting factor H’s cofactor activity and precipitating protein com-
plexes that might contribute to the formation of drusen and drusenoid 
deposits (Day and Sim, 1986; Lengyel et al., 2007; Nan et al., 2013). 
Additionally, because antioxidant and visual cycle enzymes in the retina 
require Zn, the interference of Cd could have widespread deleterious 
effects on retinal functions (Rink, 2011; Ugarte and Osborne, 2001). 
Furthermore, Cd can enhance production of ROS which results in DNA 
and protein damage, inflammation, apoptosis and angiogenesis (Cuyp-
ers et al., 2010). Population-based preventive strategies to decrease Cd 
exposure, especially by the cessation of smoking, could reduce the 
burden of nAMD. 
To our knowledge, no studies have been published that have re-
ported higher plasma levels of Ba in nAMD patients as observed in the 
current work. Some epidemiological investigations show a positive 
correlation between Ba exposure and hypertension (Nigra et al., 2016), 
which is in line with the trend in our study in which higher Ba levels 
were found in participants using antihypertensive drugs. It has been 
reported that Ba can inhibit potassium (K) channels of the 
sodium-potassium (Na/K) pump in smooth muscle cells of arteries and 
arterioles, leading to reduced blood flow (Tykocki et al., 2017). This 
suggests that higher circulating Ba levels might be associated with 
nAMD by a reduced blood flow in the choroid, where Ba is reported to be 
present (Sowden and Pirie, 1958). Furthermore, electrophysiology 
studies in human donor eyes also show that Ba is able to inhibit the Na/K 
pump at the apical and basolateral membranes of the RPE, thereby 
reducing the transport of molecules across RPE cell membranes (Quinn 
and Miller, 1992). The inverse relationship between Ba and Co levels 
seen in nAMD patients could also be of relevance, given that there is 
evidence that Co can induce expression of vascular endothelial growth 
factor (VEGF) in RPE cells (Zhang et al., 2015). However, the direct role 
of Ba in the etiology of nAMD is currently unknown, and further research 
is needed to determine the influence of elevated Ba levels on the func-
tion of RPE and choroid. 
Despite our observation of lower levels of Cr in nAMD patients, we 
were not able to identify underlying associations with demographic, 
environmental, lifestyle or genetic factors. Studies in Cr-deficient rats 
showed more phagocytized lamellar structures in the RPE, providing 
evidence that Cr has a beneficial effect on the physiology of the RPE 
(Ueda et al., 2002). Furthermore, a study in hens showed that supple-
mentation of Cr can increase serum vitamin C and E levels, and decrease 
malondialdehyde (MDA) levels( Onderci et al., 2003). MDA, which is a 
byproduct of polyunsaturated fatty acid peroxidation, has been impli-
cated in RPE dysfunction and in driving angiogenesis through the 
stimulation of VEGF production by RPE cells (Weismann et al., 2011; Ye 
et al., 2016). Thus, it is conceivable that a reduction in circulating Cr 
levels could contribute to nAMD pathology, through a loss of its pro-
tective function and induction of pro-angiogenic pathways. Several 
studies report associations between AMD and diabetes mellitus, and 
hypothesize a common disease pathway of oxidative stress caused by 
hyperglycemia and dyslipidemia leading to macular pathology (Chen 
et al., 2014). In type 2 diabetes mellitus, Cr supplementation has a sig-
nificant favorable effect on fasting glucose levels and total cholesterol 
levels. Whether supplementation of Cr is also beneficial for altering the 
disease progression towards nAMD is not known. In this regard, it would 
be informative to explore whether Cr levels are also reduced at a local 
level in the RPE. 
In AMD, supplementation of Zn has shown to be beneficial in 
reducing the progression of the disease (Age-Related Eye Disease Study 
Research Group, 2001; Chew et al., 2015; Seddon et al., 2016). In our 
study, we detected higher plasma Zn levels in participants using sup-
plements, but we did not detect significant differences in Zn levels be-
tween nAMD patients and controls. This might be due to the fact that 
only 36% of the nAMD patients reported supplement usage. The 
empirical lower limit of normal plasma Zn has been reported to be 750 
μg/L, which is very similar to the mean plasma Zn level in controls from 
our study (Table 2) (Yokoi et al., 2003). However, the plasma Zn level is 
probably not a sensitive indicator of the Zn status of an individual since 
this only represents ~0.1% of the whole-body Zn concentration (Mills, 
1988). For instance, in drusen, the local Zn levels are much higher, with 
a previous study reporting an average concentration of 500 ppm (equal 
to 500,000 μg/L) (Lengyel et al., 2007). Thus, measuring plasma Zn 
levels might not provide an accurate reflection of the local Zn levels in 
the macula of AMD patients. In addition, we analyzed equal volumes of 
plasma and calculated the amount of trace element per unit volume, 
which is in line with standard clinical biochemical practice. However, 
altered amounts of metal-binding proteins could influence the plasma 
levels of certain trace elements (including Zn). Therefore, future studies 
may also take into account the total level of plasma proteins or specific 
metal carriers, which may provide further mechanistic insights. 
Here, by simultaneously measuring 16 trace elements by ICP-MS in a 
group of nAMD patients and controls, a comprehensive overview of 
systemic trace element levels was obtained. This approach allowed us to 
identify elevated levels of Ba and Cd and decreased levels of Cr in nAMD 
patients compared to controls. Several steps were taken in order to 
prevent confounding factors that are known to influence trace element 
levels. Controls used in this study were age-matched with the nAMD 
patients. Also, demographic, environmental, lifestyle and genetic factors 
were taken into account to investigate underlying associations with 
plasma trace element levels. However, other environmental risk factors 
such as the living environment of participants (rural versus urban) or 
performing industrial or nonindustrial work, might also influence 
plasma trace element levels but were not taken into account. 
Even though this is one of the largest studies on trace element 
measurements in nAMD patients to date, our study should be considered 
as exploratory, i.e. to provide leads for follow-up research. Future 
studies should focus on replication of the findings of the current study in 
Table 3 
Significant differences in the correlations for plasma trace elements between nAMD patients and controls.   








As – Se 0.295 <0.001 0.115 0.275 0.180 0.042 
Ba – Co -0.028 0.841 -0.224 0.004 0.196 0.031 
Ba – Mn 0.040 0.752 0.358 <0.001 0.318 <0.001 
Cu – Mg 0.113 0.294 0.315 <0.001 0.202 0.022 
Mg – Mo 0.065 0.591 0.246 0.001 0.181 0.045 
Mg – Se 0.206 0.010 0.004 0.979 0.202 0.027 
Mg – V -0.136 0.164 0.114 0.282 0.250 0.007 
Mn – Sb -0.263 <0.001 -0.026 0.865 0.237 0.009 
Analysis is based on a spearman’s rho rank correlation between the different trace elements and adjusted for multiple testing using FDR correction. The threshold of 
statistical significance was defined as PFDR-value <0.05 after FDR correction. Significant correlation coefficients of nAMD patients and controls were compared using 
the “r. test” function of the “psych” package. Supplementary Table 2 provides all plasma trace element correlations. Abbreviations: As, arsenic; Ba, barium; Co, cobalt; 
Cu, copper; Mg, magnesium; Mn, manganese; Mo, molybdenum; nAMD, neovascular age-related macular degeneration; Sb, antimony; Se, selenium; V, vanadium. 
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Table 4 
Association between plasma trace element levels and demographic, environmental and lifestyle factors. 
Analyses are based on ANOVA t-tests for normally distributed trace elements, and Kruskal-Wallis H tests for non-normally distributed trace elements. Grey boxes 
denote trace elements for which there was a significant difference in plasma trace element levels between demographic categories after applying Bonferroni 
correction for 16 covariates (the Bonferroni adjusted threshold for statistical significance was defined as P < 0.003). Abbreviations: ANOVA, Analysis of variance; As, 
arsenic; Ba, barium; BMI, Body Mass Index; Ca, calcium; Cd, cadmium; Co, cobalt; Cr, chromium; Cu, copper; Fe, iron; Mg, magnesium; Mn, manganese; Mo, 
molybdenum; nAMD, neovascular age-related macular degeneration; Pb, lead; Sb, antimony; Se, selenium; V, vanadium; Zn, zinc. 
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an independent nAMD cohort; for example, a recent method that uses a 
smaller sample volume (~30 μL) may prove useful to investigate the 
levels of particular metal ions (e.g. Cu, Fe and Zn)(Abduljabbar et al., 
2019). Secondly, since we measured trace elements in plasma, this 
might not reflect the local levels in the eye. In this regard, donor eyes 
from patients with AMD were reported to have significantly higher 
levels of As, Ca, Cr, Pb, Ni and Se in choroid-RPE compared to non-AMD 
eyes (Aberami et al., 2019). Also, patients with AMD were found to have 
higher levels of Fe and lower levels of Zn within photoreceptors and 
RPE, compared to controls (Dunaief, 2006; Galin et al., 1962; Hahn 
et al., 2003). Based on our results, further investigation of Ba and Cr in 
donor nAMD eyes may be of relevance. In addition, despite AMD 
involving mainly disease processes in the macula, also drusen and sub-
retinal drusenoid deposits can be identified in the periphery. Moreover, 
RPE cells show high topographical heterogeneity between the macula 
and peripheral retina (Burke and Hjelmeland, 2005). Therefore, future 
studies could be designed to investigate topographical differences in 
trace element levels in different regions of the retina. Finally, as only 
nAMD patients were included in this study, measurement of trace ele-
ments in patients with intermediate stage AMD, geographic atrophy, or 
subtypes of neovascularization could provide new insights into the 
pathophysiology of AMD and disease progression. Studies investigating 
phenotypic characteristics show that intraretinal neovascularization is 
strongly associated with subretinal drusenoid deposits, whereas sub-
retinal and sub-RPE neovascularization is associated with drusen 
(Rabiolo et al., 2017). Therefore, it would be interesting to explore 
plasma trace element levels between these nAMD subtypes to better 
understand differences in their pathophysiology. Unfortunately, we 
were unable to carry out such an analysis here since OCT was only 
available for our EUGENDA studies from 2010; therefore we were un-
able to grade the subtype of neovascularization for half of the nAMD 
patients. 
5. Conclusion 
In conclusion, in this study we detected elevated levels of barium and 
cadmium and reduced levels of chromium in the plasma of nAMD pa-
tients. This study suggests that an imbalance in plasma trace elements 
might have a role in the pathogenesis of nAMD. These trace elements 
may be incorporated as biomarkers into models for prediction of disease 
risk and progression. Because plasma trace element levels are modifiable 
risk factors, this could lead to preventive interventions. Additionally, 
population-based preventive strategies to decrease Cd exposure, espe-
cially by the cessation of smoking, could potentially reduce the burden 
of nAMD. Future studies are warranted to investigate whether 
supplementation of Cr would have a beneficial effect on nAMD. 
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